ST. LOUIS, May 13 /PRNewswire-FirstCall/ -- Sigma-Aldrich today introduced Precisio(TM) Kinases (www.sigma.com/precisiokinases), a new collection of high quality active kinases that is expected to enable scientists to achieve greater insight into protein phosphorylation and cell signaling. Optimized for high-throughput kinase screening and profiling, Precisio Kinases allow for the characterization of cellular processes and may contribute to new therapeutic strategies for treating diseases including cancer, diabetes and hypertension.
“Precisio Kinases are engineered to have the quality and consistency scientists demand for high-throughput applications,” said Helge Bastian, Vice President of Marketing and Business Development at Sigma-Aldrich. “Combined with Sigma’s existing product lineup for kinase and phosphatase research, this new offering facilitates a greater understanding of signaling pathways and may provide the foundation for new drug and therapeutic targets.”
Protein kinases are essential in intercellular communication, mediating signal transduction in development, transcription, immune response, metabolism, apoptosis and cell differentiation. Improper kinase function plays a role in many diseases, most notably cancer, and the study of these proteins and their functions may contribute to the discovery and development of new drug targets.
Sigma-Aldrich’s new Precisio Kinases are suitable for high throughput screening and profiling. Each Precisio Kinase contains a batch-optimized assay protocol, ensuring high performance, quick implementation and consistent results in a variety of applications.
The Precisio Kinases complement Sigma-Aldrich’s existing offerings in the field of kinase and phosphatase research, including kinase antibodies, substrates, inhibitors, activators and cell-based assay kits. To learn more about Precisio Kinases and explore the no-risk trial program, visit www.sigma.com/precisiokinases.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customers’ Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.
Cautionary Statement: This release contains forward-looking statements relating to future strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company’s expectations, beliefs, intentions and the like, which involve assumptions regarding the Company’s operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.
Sigma-Aldrich and Precisio are trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.
CONTACT: Sean Battles of Sigma-Aldrich, +1-314-286-7616,
sean.battles@sial.com
Web site: http://www.sigma-aldrich.com/
